Hisam Siddiqi: Understanding Bone Marrow Trephine Morphology in MPNs
Hisam Siddiqi, Consultant Haematologist at LycaHealth, The Blackheath Hospital, Dartford and Gravesham NHS Trust, shared a post on LinkedIn:
“Understanding Bone Marrow Trephine Morphology in MPNs – A Simple Breakdown
Myeloproliferative neoplasms (MPNs) can often look similar clinically, but the bone marrow trephine provides important clues that help us distinguish between them.
Here’s a quick, simplified guide to typical findings across the main MPN subtypes, based on key features: cellularity, megakaryocyte morphology, clustering patterns, and reticulin fibrosis.
Polycythaemia Vera (PRV)
- Cellularity: Very high (panmyelosis – all cell lines increased)
- Megakaryocytes: Mildly increased
- Clusters: Usually absent
- Reticulin: Normal or slightly up
- Think: a busy marrow with everything ‘turned up.’
Essential Thrombocythaemia (ET)
- Cellularity: Normal
- Megakaryocytes: Markedly increased, hyperlobulated (‘staghorn’)
- Clusters: None or loose
- Reticulin: Normal or slightly up
- Think: lots of large, mature megakaryocytes with big, multilobed nuclei.
Pre‑Fibrotic Myelofibrosis (pre‑MF)
- Cellularity: Increased
- Megakaryocytes: Variable up; abnormally shaped, atypical, hypolobulated
- Clusters: Small, dense or loose
- Reticulin: Mildly up
- Think: dysplastic megakaryocytes plus early scarring.
Overt Myelofibrosis (MF)
- Cellularity: Often reduced
- Megakaryocytes: Increased, hypolobulated / atypical
- Clusters: Dense, tight clusters
- Reticulin: Marked fibrosis with collagen deposition
- Think: fibrotic, scarred marrow with abnormal megakaryocyte clusters.
Why this matters:
Trephine morphology remains central to accurate MPN diagnosis and helps guide prognosis and treatment decisions. Recognising these hallmark patterns can refine our diagnostic confidence and improve patient care.”

More posts featuring Hisam Siddiqi on Hemostasis Today.
-
Jul 12, 2026, 15:45Nathan Connell: Key Clinical Advances in Heavy Menstrual Bleeding and Postpartum Hemorrhage from ISTH 2026
-
Jul 12, 2026, 15:40Anne-Claire Duchez: Join Us at ISTH 2026 to Discover Our Latest Research and Meet the Team
-
Jul 12, 2026, 12:30Reduced-Dose DOACs in GI Malignancies: Toward Personalized Anticoagulation
-
Jul 12, 2026, 08:50Where the Hemophilia Community Comes Together at ISTH 2026 – EAHAD
-
Jul 12, 2026, 08:2210 Posts Not To Miss from ISTH 2026, Part 1
-
Jul 12, 2026, 07:58Brian O Mahony: Could NXT-007 Minimize the Need for Perioperative FVIII
-
Jul 12, 2026, 07:50Shayan Mohammadmoradi: Connecting the Next Generation of Hemostasis Researchers at ISTH 2026
-
Jul 12, 2026, 07:42Alexandra Yakusheva: ThrombInnov Debuts at ISTH 2026 with a Focus on Translational Research
-
Jul 12, 2026, 07:34Wolfgang Miesbach: ISTH 2026 Explores the Next Generation of APS Diagnostics